VistaGen Therapeutics (NASDAQ:VTGN) Issues Earnings Results

VistaGen Therapeutics (NASDAQ:VTGN) announced its quarterly earnings data on Friday. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.14, FiscalAI reports. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.50 million. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%.

VistaGen Therapeutics Price Performance

NASDAQ:VTGN traded up $0.00 during trading hours on Friday, hitting $0.18. The company’s stock had a trading volume of 420,414 shares, compared to its average volume of 4,567,876. The stock has a fifty day simple moving average of $0.22 and a 200-day simple moving average of $0.42. The company has a market capitalization of $8.01 million, a P/E ratio of -0.11 and a beta of 0.49. VistaGen Therapeutics has a twelve month low of $0.16 and a twelve month high of $5.14.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Monday, August 31st. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $0.95.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines. Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder. The company’s pipeline has also included PH80, an intranasal therapy investigated for migraine and other neurological conditions, and PH10, an intranasal neuroactive compound studied for depressive disorders.